股票研究 /[Table_Date] 15 May 2025 PC 一始，鸿蒙新篇 [Table_Industry] 计算机 [Table_Invest] 评级： 增持 [table_Authors] 本报告导读： 鸿蒙 PC 从内核开始重构 OS，生态方面有 2000+融合应用加速适配，预计在 AI 和万 物互联新战场占据一席之地；鸿蒙 PC 的推出同时也繁荣了整个鸿蒙 OS 生态。 投资要点： 踪 报 告 证 券 研 究 报 告 请务必阅读正文之后的免责条款部分 股 票 研 究 跟 [Table_Summary] 投资建议：鸿蒙 PC 的推出将完善华为"1+8+N"布局，有望在 AI 时代 占据先机，成为万物互联时代的入口。推荐标的，中国软件国际， 软通动力，新大陆，润和软件，拓维信息；相关标的，东方中科， 智微智能，常山北明。 鸿蒙 PC 从内核开始重构 OS。①鸿蒙底座方面，鸿蒙内核是系统的 核心基础，方舟引擎负责提升性能，分布式特性支持设备间的资源 共享，星盾架构保障系统安全，还有 ArkTS（编程语言）、ArkUI（界 面框架）、DevEco（开发工具）。②上层组件方面，Harmony OSSDK ...

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 46.67, compared to the current price of RMB 40.13 [1][8]. Core Insights - In 2024, the company is projected to achieve revenue of RMB 2.87 billion (+0.96%) and a net profit attributable to shareholders of RMB 501 million (+0.20%). The recurring net profit attributable to shareholders is expected to be RMB 496 million (+3.18%) [8]. - The company is adjusting its EPS forecasts for 2025 and 2026 to RMB 1.26 and RMB 1.36, respectively, and adding a forecast for 2027 of RMB 1.49. The 2025 PE is set at 37X [8]. - The dental implant segment shows strong performance, while orthodontics is under short-term pressure due to consumption downgrade. By the end of 2024, the company will have over 260,000 sqm of medical service area and 3.53 million outpatient visits [8]. - The company has completed five major dental clusters in Zhejiang province and is expanding its "regional main hospital + branch" model [8]. Financial Summary - The company’s revenue and net profit projections for the coming years are as follows: - 2023A: Revenue of RMB 2.85 billion, Net Profit of RMB 500 million - 2024A: Revenue of RMB 2.87 billion, Net Profit of RMB 501 million - 2025E: Revenue of RMB 3.00 billion, Net Profit of RMB 564 million - 2026E: Revenue of RMB 3.20 billion, Net Profit of RMB 609 million - 2027E: Revenue of RMB 3.40 billion, Net Profit of RMB 665 million [4][5]. - The company’s net asset return rate is projected to be around 12.9% for 2025 and 13.0% for 2027 [5]. Business Expansion Strategy - The company is shifting its provincial expansion strategy from traditional self-built models to a combination of acquisitions and asset-light franchising, aiming for a national network at lower costs and higher efficiency [8]. - The company has opened 44 Dandelion branches in 2024, with 60% achieving break-even, and plans to open additional branches in 2025 [8].

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 24.18, compared to the current price of RMB 20.89 [1][9]. Core Views - The company is exploring growth drivers across four major business areas, with a focus on chronic disease management and infectious disease testing. The revenue for 2024 is projected to be RMB 3.07 billion, representing a growth of 10.85%, while the net profit attributable to shareholders is expected to reach RMB 562 million, an increase of 15.18% [1][9][10]. - The report highlights breakthroughs in luminescence, molecular diagnostics, and pathology, with significant advancements in product performance and market access, particularly in non-U.S. overseas markets [11][12]. Financial Summary - The financial projections indicate a revenue increase from RMB 2,765 million in 2023 to RMB 3,065 million in 2024, with a year-on-year growth of 10.8%. Net profit is expected to rise from RMB 488 million in 2023 to RMB 562 million in 2024, reflecting a growth of 15.2% [3][9]. - Earnings per share (EPS) forecasts have been adjusted to RMB 1.34 for 2025 and RMB 1.57 for 2026, with a new forecast of RMB 1.82 for 2027 [9][10]. Business Performance - In the infectious disease testing segment, revenue is projected to be RMB 1.04 billion in 2024, a growth of 9.50%. The chronic disease management segment is expected to generate RMB 1.37 billion, marking a significant increase of 22.38% [10]. - The company has established a robust international sales team, exporting products to over 150 countries, which has contributed to rapid growth in non-U.S. markets [12].

采浆规模稳步提升，静待新产能释放 派林生物(000403) ——派林生物 2024 年报点评 股票研究 /[Table_Date] 2025.05.04 2025-05-15 [Table_Industry] 医药/必需消费 [Table_Invest] 评级： 增持 [Table_Target] 目标价格： 27.86 [Table_CurPrice] 当前价格： 21.90 [Table_Market] 交易数据 总市值（百万元） 16,011 总股本/流通A 股（百万股） 731/727 流通 B 股/H 股（百万股） 0/0 本报告导读： 公司当前共有 36 个在营浆站，2024 年采浆量超 1400 吨，二期产能扩产完成后投浆 能力和产品工艺水平都将进一步提升，维持优于大市评级。 投资要点： | [Table_Finance] 财务摘要（百万元） | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入 | 2,329 | 2,655 | 3,090 | 3,460 | 3,834 | ...

14 May 2025 京东健康 JD Health International (6618 HK) 25Q1 业绩大幅超市场预期，建议关注后续大促季表现和即时零售布局展开 25Q1 beat, attention on upcoming promotional season and instant retail initiatives 研究报告 Research Report [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$39.95 目标价 HK$42.90 HTI ESG 4.0-4.0-4.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$127.83bn / US$16.40bn 日交易额 (3 个月均值) US$95.85mn 发行股票数目 3,200mn 自由流通股 (%) 32% 1 年股价最高最低值 HK$40.80-HK$19.82 注：现价 HK$ ...

Investment Rating - The investment rating for JD Logistics is maintained at "Outperform" [2][5]. Core Views - JD Logistics reported Q1 2025 results with revenue of RMB 46.97 billion, reflecting a year-on-year growth of 11.5%, and a Non-IFRS net profit of RMB 0.751 billion, up 13.4% year-on-year [3][10]. - The company is expected to achieve total revenue of RMB 203.3 billion in 2025, representing an 11.2% increase, with a Non-IFRS net profit margin projected at 4.0% [11]. Financial Performance Summary - Revenue projections for JD Logistics are as follows: - 2024: RMB 182.84 billion - 2025: RMB 203.28 billion (+11%) - 2026: RMB 225.67 billion (+11%) - 2027: RMB 248.56 billion (+10%) [4][8]. - Net profit forecasts are: - 2024: RMB 7.92 billion - 2025: RMB 8.21 billion (+4%) - 2026: RMB 11.11 billion (+35%) - 2027: RMB 13.23 billion (+19%) [4][8]. - The gross profit margin (GPM) is expected to improve from 10.2% in 2024 to 13.0% by 2027 [4][8]. Market Position and Strategy - JD Logistics has strengthened its integrated supply chain services, with revenue from integrated supply chain clients reaching RMB 23.2 billion, a 13.2% increase, driven by higher revenue from JD Group and a 13.1% increase in the number of integrated supply chain clients [3][4]. - The company is investing in enhancing service quality and expanding its customer base, with a focus on improving operational efficiency and inventory management [4][5]. Valuation - The target price for JD Logistics is set at HKD 19.79, based on a 15X PE valuation for FY25E [2][11].

Investment Rating - The report assigns a rating of "Outperform" for Samsonite, indicating an expected total return over the next 12-18 months that exceeds the return of its relevant broad market benchmark [20]. Core Insights - Samsonite's 1Q25 revenue and profit performance were under pressure, with net sales declining 4.5% year-on-year to $797 million, primarily due to weak demand in North America and China, along with a high base from the previous year [2][9]. - The company aims to maintain gross margin levels despite challenges, with a gross margin of 59.4% in 1Q25, down 100 basis points year-on-year [2][9]. - Adjusted EBITDA decreased by 20.9% year-on-year, reflecting negative leverage effects from lower gross margins and sales, resulting in an adjusted EBITDA rate of 18.8% [2][9]. - Adjusted net income fell by 40.3% year-on-year, driven by the decline in adjusted EBITDA, increased depreciation, net interest expense, and a higher effective tax rate [2][9]. - The company reported a negative adjusted free cash flow of $41 million in 1Q25, attributed to the decline in EBITDA and an increase in net working capital [2][9]. Revenue Performance by Region - Sales in Asia and North America were weak, with Asia revenue down 7% year-on-year, and North America revenue declining 8% [3][10]. - European sales continued to show strong growth, with a 4.4% year-on-year increase, supported by positive growth across all core brands [3][10]. - Latin America sales remained flat year-on-year, with a notable decline in Mexico due to lower consumer confidence [3][10]. Channel Performance - The Direct-to-Consumer (DTC) channel performed well, accounting for 38.2% of revenue in 1Q25, with e-commerce contributing 10.6% and offline retail 27.5% [4][11]. - The offline retail business saw a decline of 2.6%, primarily due to reduced customer traffic, while wholesale business declined by 6.1% year-on-year [4][11]. Tariff Policy and Mitigation Strategies - The U.S. tariff policy remains unclear, causing caution among consumers and wholesale customers [5][12]. - The company has reduced its sourcing from China to 14% and plans to further decrease this by year-end, leveraging a diversified sourcing platform to mitigate potential tariff impacts [5][12]. Future Guidance - Management expects 2Q25 net sales growth to be similar to 1Q25, with net revenue guidance down mid-single digits on a constant currency basis [6][13]. - Long-term growth is anticipated to be supported by strong travel trends, despite short-term macroeconomic uncertainties affecting consumer demand [6][13].

Investment Rating - The report initiates coverage with an OUTPERFORM rating, targeting a price of HK$13.40 from a current price of HK$8.06 [2]. Core Insights - The company is focused on precision therapy with small molecules in oncology and is expected to achieve profitability in 2024, driven by significant revenue growth from licensing agreements [3][4]. - The core pipeline includes Pimicotinib, which is anticipated to submit a global NDA in 2025, with potential peak sales exceeding USD 2 billion [4][19]. - The company has a robust pipeline targeting FGFR mutations, with potential coverage for approximately 1.9 million patients globally [4][39]. Financial Projections - Revenue projections for FY24, FY25, FY26, and FY27 are RMB 504 million, RMB 595 million, RMB 420 million, and RMB 560 million respectively, with net profit expected to reach RMB 28 million in FY24 [3][8]. - The company is projected to achieve a net profit of RMB 173 million by FY27, with a significant increase in diluted EPS from RMB 0.04 in FY24 to RMB 0.25 in FY27 [3][8]. Pipeline Development - The company has advanced clinical trials for Pimicotinib, which has shown promising results in treating TGCT with an ORR of 87.5% [28]. - The pipeline includes multiple candidates targeting FGFR, with ABSK011 and ABSK061 expected to achieve peak sales of over USD 3 billion collectively [14][39]. - The oral PD-L1 inhibitor ABSK043 is positioned to capture a share of the USD 52 billion PD-(L)1 market, with a projected launch in 2030 [6][14]. Management and Team - The management team has extensive experience in drug development and commercialization, with backgrounds in leading pharmaceutical companies [11][13]. - The company emphasizes early-stage R&D, allocating over 30% of its budget to this area, which supports a pipeline of over 15 preclinical candidates [7][10]. Market Opportunity - The global market for PD-(L)1 therapies is substantial, with no approved small molecule PD-1/PD-L1 drugs currently available, indicating a significant opportunity for the company's oral PD-L1 inhibitor [6][14]. - The unmet medical needs in the treatment of cGvHD and TGCT present additional market opportunities for the company's pipeline [33][25].

wo[Table_Title] Research Report 14 May 2025 电子 Technology 红杉 AI 峰会六大关键议题解读（4）： AI 商业化范式转移，从"点击"迈向"结果" Interpretation of the Six Key Topics of the Sequoia AI Summit (4): The Shift in AI Commercialization Paradigm, from 'Clicks' to 'Results' 姚书桥 Barney Yao 邓雅文 Linda Deng barney.sq.yao@htisec.com linda.yw.deng@htisec.com [Table_yemei1] Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件： 在 2025 年红杉 AI 峰会上，关于 AI 商业化路径的讨论中，"从点击逻辑向结果逻辑的转变"成为核心共识。过去，AI 产品的价值往往通过用户的点击量、使用时长等指标来衡量，这体现了一种 "使 ...

wo[Table_Title] Research Report 14 May 2025 电子 Technology 红杉 AI 峰会六大关键议题解读（5）： AI 商业化范式转移，从"模型调用"迈向"组织 结构调用" Interpretation of the Six Key Topics of the Sequoia AI Summit (5): The Shift in AI Commercialization Paradigm from "Model Invocation" to "Organizational Structure Invocation" [Table_yemei1] Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件： 在 2025 年红杉 AI 峰会上，关于 AI 商业化路径的讨论中，"模型调用转向组织结构调用"成为核心共识。当前 AI 行业 将算力规模与参数堆叠视为核心竞争力，而真正的掣肘在于组织、流程与工具链未能构建适配智能运作的结构。未 来的竞争将聚焦于谁能够构建更高效的协作 ...